Nuclear Medicine/ Radio-pharmaceuticals Market Overview

The global nuclear medicine/ radio-pharmaceuticals market is estimated to be worth over USD 15.5 Bn in 2033 and is expected to grow at CAGR of 11.0% during the forecast period (2024-2033). Nuclear medicine/ radiopharmaceuticals came into view as a significant breakthrough within the pharmaceutical industry, representing an active convergence of healthcare, business, and technology.

Nuclear medicine harnesses the potential of radiopharmaceuticals and radioisotopes to detect and address a vast range of health challenges. Application of Gallium-68 (Ga-68) radiopharmaceuticals, such as Gallium-68 DOTATATE, in the sphere of oncology, can be considered as one of the striking examples of this breakthrough. The emergence of radiopharmaceuticals hasbrought an immense variation in the precision of cancer diagnosis and management. Ga-68 DOTATATE, positron emission tomography (PET) agent, has proven to be agame-changer in the medical treatment of neuroendocrine tumors (NETs). It helps in earlydiagnosis, accurate classification, and more specializedtherapy regimens, substantiallyenhancing patient outcomes.

The nuclear medicine/radiopharmaceutical domain is also extensively developing in the cardiology sector, since Technetium-99m (Tc-99m) is gaining immense traction in the medical treatment of myocardial perfusion imaging. The usage of Technetium-99m (Tc-99m) allows the early diagnosis of cardiac disorders and helps in risk evaluation, minimizing the burden of heart diseases at length. All in all, nuclear medicine/radiopharmaceuticals havecertainly brought a new age of invention and profitability within the pharmaceutical sector. Therefore, the global nuclear medicine/radiopharmaceutical market is estimated to witness significant growth, taking into account continuous advancements in cancer diagnosis and cardiology, ultimately generating lucrative opportunities for growth and associations that will remodel the medication landscape in the coming years. 

Figure 1. Nuclear Medicine/ Radio-pharmaceuticals: Market Size

Get more details on this report - Request Free Sample

Key Market Insights

The global nuclear medicine and radiopharmaceuticals market is experiencing a breakthrough moment with numerousdefinite trends. Among all, one notableadvancement is the surge in adoption of theranostics, a blend of diagnostics and targeted therapy. This approach comprises the utility of radiopharmaceuticals to diagnose medical conditions as well as also to treat them, delivering a more customized and efficient healthcare solution. The rise in prevalence of chronic medical illnesses like neurological disorders and cancer has paved its way toupswing in demand for these state-of-an-art theranostic solutions, causing a ripple effect in the field of nuclear medicine.

Along with that, the market is undergoing itsgreatest breakthroughs in the manufacturing of radiopharmaceuticals, such as making use of cyclotrons and accelerator-based technology for isotope production. This move is improving the attainability and quality of radiopharmaceuticals and widening the scope of their applications. Moreover, regulatory authorities are progressivelyrationalizing approval procedures, facilitating quicker market access for novel radiopharmaceuticals, and supporting research and development in the sector.

Current Market Landscape: Nuclear Medicine/ Radio-pharmaceuticals Offering Efficient Treatment Recourse

In the current age, the nuclear medicine/radiopharmaceutical market is leading the way to continuous innovations and significant growth. Some of the major factors that are primarily propelling the industry to witness an upsurge in demand includes growing incidence of cancer, neurological and cardiovascular disorders along with the increasing focus on precision medicine.

The business landscape is characterized by large-scale investments in research and development, with a robust pipeline of radiopharmaceutical products in distinctphases of clinical trials. These comprisespotential products for neuroimaging, cancer treatment, and cardiac applications.For instance, Telix, a biopharmaceutical company geared towards the progress and commercialisation of diagnostic and therapeutic radiopharmaceuticals, proclaims that a first patient has been dosed in a phase I study of the company’s investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma, the most common and aggressive form of primary brain cancer.

In the similar instance, GE Healthcare aims to strengthen its portfolio with a couple of pipeline radiopharmaceuticals, one for Positron Emission Tomography (PET) and one for Single-Photon Emission Computed Tomography (SPECT) imaging.The company, in recent times, stated the first patient dosed in the Phase III clinical trial for a PET radiopharmaceutical imaging agent which intends to support in the analysis of adult patients with suspected Parkinsonian syndromes, upholds research and enhance patient care. It is noteworthy that GE Healthcare is beforehand a worldwide leader with DaTscan ([123I]-ioflupane), used in SPECT imaging across more than 40 countries globally.Taking into account advancing technologies, normative changes, and the evolution of pipeline products for a profound understanding and insights of this dynamic and crucial sector.

Market Dynamics

Market Drivers

Continuous Regulatory Support for Accelerated Approvals

The incessant support from the regulatory authorities for consistent clinical trials and approvals plays a major role in the significant growth of the global nuclear medicine/ radiopharmaceutical market over the coming years. The regulatory support facilitates the evolution and commoditization of novel and advanced radiopharmaceuticals, expediting their swift advent into clinical use. Moreover, the regulatory assistance and approvals also plays a substantial role for a market where speed and precision can straightwayinfluence patient care.

It is also worth noting that the regulatory agencies, especially the U.S. Food and Drug Administration (FDA), have presented programs and designations that emphasize and quicken the approval of up-and-coming radiopharmaceuticals. As an example, the FDA's "Fast Track" designation and "Breakthrough Therapy" status are intended to rationalize the evolution process for drugs dealing withvital unmet medical needs. These programs provide opportunities for cyclic interactions with regulatory agencies, possiblyresulting toaccelerated clinical trials and approvals.

Furthermore, regulatory support also advocates heavy investments for R&D as it encourages investor confidence, gaining capital to the nuclear medicine/radiopharmaceutical sector. Owing to such factors, the global nuclear medicine/radiopharmaceutical market is projected to grow at a considerable pace over the forthcoming years.

Market Restraints

With regard to numerous advantages of nuclear medicine/ radio-pharmaceuticals, the market faces several challenges due to the unique characteristics and requirements associated with these potent pharmaceutical products. Some of the key market challenges include:

• Short Shelf-life of Radiopharmaceuticals:Radiopharmaceuticals generallydeteriorateat a rapid pace, usually within hours or days, needingeffectivemanufacturing, allocation, and usage. This brief window restricts their shelf life and demandsaeffectively coordinated supply chain and infrastructure for timely delivery to healthcare facilities.
• Supply Chain Shortcomings: The worldwide supply chain for radiopharmaceuticals is complex and rests on the timely access of radioisotopes, which can be interrupted by factors like reactor stoppages, transportation disputes, or geopolitical matters. These supply chain shortcomingsare likely to pave the way to variations in product availability and strike market equivalence.

Market Opportunities

Sharp Rise in Applications of Precision Medicines & Targeted Therapies

The consistent advances in healthcare have encouraged a move towards customized treatment approaches, and radiopharmaceuticals are coming at the forefor this revolutionary wave. By taking into account the distinguishing features of radioisotopes, that enables for meticulous targeting and the distribution of therapeutic payloads, nuclear medicine is placed to presume a key role in the future of healthcare sector.

Along with that, since the geriatricworldwide population persists to rise, there is a significant upsurge in the demand of diagnostic tools and therapies to address age-associated conditions.Radiopharmaceuticals possess the capability to help in early disease detection, surveillance, and management, making them a valued possession for handling age-associated health concerns. Attributed to such factors, the global nuclear medicine/radiopharmaceutical market is estimated to witness lucrative opportunities over the forthcoming years.

Market Trends

Exploring Novel Radioisotopes:The continuous pursuit for advanced and improved diagnostic capabilities and therapeutic alternatives is primarily strengthening the trend, hence propelling the market growth. Several pharmaceutical companies and researchers are consistentlyin quest of novel radioisotopes with specializedcharacteristics that can enhance the sensitivity, precision, and safety of radiopharmaceutical applications.Notably, taking into accountrestrictions on the manufacturing of specific alpha emitting isotopes, biopharmaceutical companies are setting out to examine alternative radioisotopes such as 223Radium,211At, and 212Lead which presentexciting opportunities for both imaging as well as therapy. Broadly, the trend of seeking novel radioisotopes is set totransform nuclear medicine by augmenting the range of diagnostic and therapeutic prospects, enhancing patient care, and alleviating some of the logistical hurdlesrelated with availability and supply.

Optimizing Efficacy in Radiopharmaceuticals: The modernistic cancer therapies are seldomconducted as monotherapies and more frequently as a merger of two or more agents. During TRP US 2023, a criticaland constant subject of discussion prevailed around the application of this idea to the radiopharmaceutical domain. The idea is to utilize nuclear medicine/radiopharmaceuticals in combination with an assorted array of other substances, such as chemotherapeutics, immunotherapies, radioprotectors, and radiosensitizers. It is important to note that, this approach has demonstrated considerable potential beforehand, with severalcontinuous trials comprising both established and evolving radiopharmaceuticals.

Nuclear Medicine/ Radio-pharmaceuticals Market: Key Segments

By Type

• Diagnostic
• Therapeutic

By Modality

• SPECT
• PET
• Alpha-emitters
• Beta-emitters
• Brachytherapy

By Application

• Oncology
• Cardiology
• Neurology
• Thyroid
• Others

By Procedures

• Oncology
• Cardiovascular
• Central Nervous System
• Endocrine
• Skeletal
• Gastrointestinal
• Genito-urinary
• Pulmonary
• PET & PET-CT
• Therapeutic
• Others

By End-user

• Hospitals and diagnostic centers
• Research institutes

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Nuclear Medicine/ Radio-pharmaceuticals Market: Segmental Analysis

Based on Type, the global nuclear medicine/ radio-pharmaceuticals market is divided into diagnostic and therapeutic. The diagnostic market segment held the largest share in the market, attributing to the dramatic rise in the utilization of SPECT and PET imaging along with the upgrades in the radiotracers.

Based on the End User, the market is segmented into hospitals and diagnostic centres and research institutes. Factors like growing number of diagnostic procedures carried out in hospitals and diagnostic centres along with the increased demand of early diagnosis is aiding the hospital anddiagnostic centres segment to lead the market.

Nuclear Medicine/ Radio-pharmaceuticals Market: Regional Analysis

North America is dominating the global nuclear medicine/radiopharmaceutical market. This is owing to the advancements in the novel technologies for radioisotopes production, increased investments for research and development, and continuous rise in government funding, North America is dominating the global market.

Figure 4. Nuclear Medicine/ Radio-pharmaceuticals Market: Distribution by Region

Get more details on this report - Request Free Sample

Leading Nuclear Medicine/ Radio-pharmaceuticals Developers

Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the nuclear medicine/ radio-pharmaceuticals market, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biopharmaceutical industry. Key takeaways of the nuclear medicine/ radio-pharmaceuticals market are briefly discussed below.

The report includes the list of players operating in the global nuclear medicine/ radio-pharmaceuticals market. Some of the key players include:

• Advanced Accelerator Applications S.A.
• Bayer AG
• Bracco Imaging S.p.A
• Curium
• Cardinal Health, Inc.
• Eczacibasi-Monrol Nuclear Products
• General Electric Co.
• GE Healthcare
• IBA Group
• Isotope JSC
• Jubilant Draximage Inc.
• Lantheus Medical Imaging, Inc.
• Medtronic, plc. (Covidien, acquired by Medtronic)
• Mallinckrodt plc.
• Nordion Inc.
• NorthStar Medical Radioisotopes
• NTP Radioisotopes SOC Ltd.
• PharmaLogic Holdings Corp.
• Siemens Healthineers

Recent Developments in the Nuclear Medicine/ Radio-pharmaceuticals Market

Several recent developments have taken place in the field of nuclear medicine/ radio-pharmaceuticals, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis. chronologically

• In January 2023, NorthStar Medical Radioisotopes achieved a major milestone in advancing its novel technology for non-uranium-based production of the crucial medical radioisotope, molybdenum-99 (Mo-99).
• In October 2022, Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18F-rhPSMA-7.3 clinical data and images. Siemens Healthineers plans to evaluate the data to improve its analytics and artificial intelligence (AI)-based algorithms for prostate cancer across its advanced PET/CT imaging software.
• In March 2022, Curium announced that its generic version of DaTscan (Ioflupane I 123 Injection) was approved, by the U.S. Food and Drug Administration (FDA). Ioflupane I 123 Injection is a single-photon emission computed tomography (SPECT) brain imaging agent used to assist in the evaluation of adult patients with suspected Parkinsonian Syndromes.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table: